Tenax Therapeutics, Inc
Tenax Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on developing cardiopulmonary therapies for pulmonary hypertension and related heart failure conditions. Its pipeline centers on levosimendan and imatinib, two repurposed drug candidates being advanced through clinical development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical development of levosimendan as a therapy for pulmonary hypertension and related cardiopulmonary disease.
Clinical development of imatinib for pulmonary arterial hypertension and other potential indications.
Execution of preclinical work and clinical studies needed to advance product candidates.
Customers
Tenax Therapeutics does not sell commercial medicines today; its primary stakeholders are clinical trial participants, investigators, and research sites that support development programs. If approved, its eventual customers would be physicians, hospitals, and specialty treatment centers serving patients with pulmonary hypertension and heart failure-related cardiopulmonary disease.
They enroll patients, run studies, and generate the clinical evidence needed for regulatory approval.
They shape trial design and would be the main prescribers if the therapies are approved.
They would administer or prescribe approved cardiopulmonary therapies in advanced disease settings.
The target patient population for levosimendan and imatinib development programs.
Strategy
The company is prioritizing levosimendan while continuing to evaluate imatinib as a longer-term program for pulmonary arterial hypertension. Its strategy is to use repurposed drugs with established safety histories to reduce development risk and focus capital on late-stage clinical evidence generation.
This is the lead asset and the main path to potential regulatory and commercial value.
Imatinib provides a second cardiopulmonary program that could broaden the pipeline if development is successful.
Clinical-stage drug development requires substantial capital before any product revenue is available.
Geography
Tenax Therapeutics is headquartered in the United States and conducts its development activities through U.S.-based corporate operations and clinical programs. Its business is geographically tied to where clinical trials are run and where future regulatory approvals and commercialization would occur, with the U.S. being the core operating base.
Risks
Tenax faces the core risks of clinical-stage drug development: trial enrollment uncertainty, clinical failure, regulatory delay, and the possibility that additional capital will be needed before commercialization. Because its value depends on a small number of product candidates, setbacks in levosimendan or imatinib could materially affect the business.
The company depends on successful trial outcomes for levosimendan and imatinib.
Exposure: Levosimendan and imatinib programs
Trial timelines depend on recruiting eligible pulmonary hypertension patients.
Exposure: LEVEL trial and future Phase 3 studies
The company may need additional capital to complete development and commercialization.
Exposure: Operating runway and future trial funding
FDA approval requires positive clinical evidence and acceptable safety/efficacy data.
Exposure: All product candidates
A small number of programs means one setback can disproportionately affect valuation.
Exposure: Levosimendan and imatinib
Accounting
Judgemental itemsTrial costs are recognized as services are received, requiring estimates for CRO and site obligations.
Impact: Affects R&D expense and liabilities
Equity awards are a meaningful compensation tool for a development-stage company.
Impact: Affects operating expenses and equity dilution
Recent offerings included pre-funded warrants and warrants that may require careful classification and valuation.
Impact: Affects equity, liabilities, and financing-related gains or losses
Excess cash is invested in money market instruments and high-quality bonds, which must be measured appropriately.
Impact: Affects interest income and balance sheet presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Tenaya Therapeutics, Inc.
TNYA · Biological Products, (No Diagnostic Substances)
Tenaya Therapeutics is a U.S.-based clinical-stage biotechnology company focused on discovering and developing therapies for heart disease.
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
Last updated: 29/04/2026